The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| TECX | -61.79% | -90.67% | -37.78% | -3% |
| S&P | +17.53% | +93.66% | +14.13% | +24% |
Tectonic Therapeutic, Inc. engages in discovery and development of therapeutic proteins & antibodies. The company was founded by Timothy A. Springer and Andrew Kruse in 2019 and is headquartered in Watertown, MA.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.34M | -28.8% |
| Market Cap | $371.02M | 52.9% |
| Market Cap / Employee | $7.27M | 0.0% |
| Employees | 51 | 292.3% |
| Net Income | -$19.98M | -57.7% |
| EBITDA | -$21.99M | -97.1% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $287.38M | 55.2% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.19M | -87.9% |
| Short Term Debt | $1.76M | -7.6% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -26.97% | 3.4% |
| Return On Invested Capital | 521.34% | 572.3% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$14.72M | 2.4% |
| Operating Free Cash Flow | -$14.72M | 2.4% |
| Metric | Q4 2023 | Q1 2024 | YoY Change | ||
|---|---|---|---|---|---|
| Price to Earnings | 4.93 | 1.85 | - | ||
| Price to Book | 2.68 | 4.53 | 1.87 | 1.23 | 77.73% |
| Price to Tangible Book Value | 2.68 | 4.53 | 1.87 | 1.23 | 77.73% |
| Enterprise Value to EBITDA | -15.10 | -40.43 | -0.01 | -3.90 | -132.56% |
| Return on Equity | -36.3% | -42.1% | -30.1% | -29.3% | -15.18% |
| Total Debt | $2.98M | $3.30M | $2.63M | $1.94M | -43.58% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
